Strategic Board Growth New board member appointment signals alignment with experienced leadership and potential for stronger governance, networking, and access to partnerships. Leverage Mark Murcko's expertise to open doors with large pharma and clinical development collaborators.

Ultra-High DAR ADC Opportunity Focus on selling partnerships or services around ultra-high DAR ADC engineering and next-generation polymer chemistry capabilities. Target biopharma companies pursuing next-gen antibody-drug conjugates seeking enhanced stability, potency, or reduced off-target effects.

Funding Readiness With notable revenue scale and recent funding, there is appetite for collaboration, joint development agreements, or milestone-driven partnerships. Position co-development or sponsored research opportunities to accelerate programs.

Mid-Sized Biotech Target Company size (11–50 employees) indicates agility and openness to outside collaborations. Prioritize outreach to mid-market pharma and contract research organizations seeking innovative ADC tech without the burden of large vendor ecosystems.

Tech Stack Synergy Leverage their technology footprint and industry tools to propose integration-friendly solutions, data collaboration, and security-conscious partnerships. Emphasize compatibility with existing digitalenvironments and scalable GMP-like processes.